Vanda Pharmaceuticals (VNDA) EBT Margin (2010 - 2026)
Vanda Pharmaceuticals (VNDA) reported EBT Margin of 93.63% for Q1 2026, down 1896.0% on a YoY basis from 5.21% in Q1 2025, and down 40.97% sequentially from 66.42% in Q4 2025.
Vanda Pharmaceuticals (VNDA) EBT Margin (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals (VNDA) has 17 years of EBT Margin data on file, last reported at 93.63% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin fell 1896.0% year-over-year to 93.63%; the trailing twelve-month figure through Mar 2026 stood at 68.74% (down 4111.0% YoY), and the FY2025 full-year result was 64.16%, down 5263.0% from the prior year.
- EBT Margin retreated to 93.63% in Q1 2026, from 66.42% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 14.91% in Q4 2022 to a low of 93.63% in Q1 2026.
- A 5-year average of 21.8% and a median of 10.93% in 2024 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin soared 2141 bps in 2023 and tumbled 6485 bps in 2025, its largest moves.
- Tracing VNDA's EBT Margin over 5 years: stood at 14.91% in 2022, then plunged by 125 bps to 3.67% in 2023, then slumped by 233 bps to 12.22% in 2024, then plunged by 444 bps to 66.42% in 2025, then tumbled by 41 bps to 93.63% in 2026.
- Business Quant data shows VNDA's EBT Margin at 93.63% in Q1 2026, 66.42% in Q4 2025, and 50.46% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Vanda Pharmaceuticals | 318.71 Mn | 116.40 Mn | 48.56 Mn | -93.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -93.63% |
| Dec 31, 2025 | -66.42% |
| Sep 30, 2025 | -50.46% |
| Jun 30, 2025 | -66.34% |
| Mar 31, 2025 | -74.67% |
| Dec 31, 2024 | -12.22% |
| Sep 30, 2024 | -13.10% |
| Jun 30, 2024 | -10.93% |
| Mar 31, 2024 | -9.83% |
| Dec 31, 2023 | -3.67% |
| Sep 30, 2023 | -0.31% |
| Jun 30, 2023 | 5.63% |
| Mar 31, 2023 | 8.85% |
| Dec 31, 2022 | 14.91% |
| Sep 30, 2022 | 8.36% |
| Jun 30, 2022 | 5.89% |
| Mar 31, 2022 | -12.57% |
| Dec 31, 2021 | 12.66% |
| Sep 30, 2021 | 15.30% |
| Jun 30, 2021 | 18.56% |